BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Journal Article in Diabetes Therapy by Author from Sansum Diabetes Research Institute Concludes That Insulet Corporation's OmniPod System Can Improve Diabetes Management for People With Type 1 Diabetes


9/30/2010 8:40:47 AM

SANTA BARBARA, CA--(Marketwire - September 29, 2010) - A new article, published this month in Diabetes Therapy, provides a comprehensive review of the OmniPod Insulin Management System (Insulet Corp., Bedford MA, USA) (NASDAQ: PODD) -- an automated, tube-free insulin pump that can be controlled wirelessly through a handheld device containing an integrated blood glucose meter. Written by Howard C. Zisser M.D., Director of Clinical Research and Diabetes Technology at Sansum Diabetes Research Institute, the article concludes that the OmniPod System improves upon existing conventional insulin delivery products and can benefit almost any patient with type 1 diabetes.

"For many patients with type 1 diabetes, continuous subcutaneous insulin infusion therapy is the only way to reach acceptable glucose control levels," said Dr. Zisser. "The OmniPod Insulin Management System improves upon conventional delivery systems by allowing precise, round-the-clock insulin management coupled with a convenient tube-free design and an intuitive user interface."

Unlike multiple daily injection (MDI) therapy, typically requiring four separate manually administered doses in a 24-hour period, the OmniPod Insulin Management System can provide uninterrupted and steady insulin delivery to patients.

Dr. Zisser also notes that the OmniPod Insulin Management System provides a number of advantages to the patient with respect to comfort and general ease of use. The device's handheld Personal Diabetes Manager (PDM) enables easier set-up and fully-automated cannula insertion. The watertight Pod also provides consistent, uninterrupted insulin delivery because patients do not need to disconnect for activities like bathing or swimming. These features, coupled with the ability to track daily, monthly, and quarterly progress may also help to empower patients and improve compliance.

Dr. Zisser also noted that a review of past clinical studies further validates the utility of the OmniPod Insulin Management System. Previous peer-reviewed publications have documented a statistically significant decrease in glycated hemoglobin levels (or A1C levels, used to determine average plasma glucose concentration over time), significantly less variation in insulin delivery compared to pumps with tubing in a laboratory environment, and a patient preference over conventional devices.

About Sansum Diabetes Research Institute
Sansum Diabetes Research Institute is a non-profit research center devoted to the prevention, treatment and cure of diabetes through research and education. In particular, it is known for its work on methods to detect and chart the progress of diabetes and its expertise in new diabetes technology.

About Insulet Corporation
Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. Founded in 2000, Insulet is based in Bedford, MA.

About the OmniPod Insulin Management System
The OmniPod Insulin Management System is the world's first tubing-free insulin pump. OmniPod offers people living with insulin-requiring diabetes all the benefits of insulin pump therapy, with unprecedented freedom, comfort and ease. OmniPod has just two components: the small, discreet, watertight Pod, worn almost anywhere on the body to hold and deliver insulin; and the PDM (Personal Diabetes Manager), a hand-held device that communicates wirelessly to program the Pod, calculates suggested doses and has a built-in FreeStyle® blood glucose meter. For more information, please visit: www.myomnipod.com


Contact:
Howard C. Zisser. M.D.
Email Contact

Media contacts:
Erich Sandoval
Email Contact
805-667-8402

Stephanie Marks
Email Contact
212-843-0211


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->